Associated Papers
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I et al.
Journal of Translational Medicine, 2024
38750555 (PubMed )
Supplement: 12967_2024_5227_MOESM10_ESM.xlsx › S10
Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.
Lian B et al.
Frontiers in Endocrinology, 2024
Bilateral Pheochromocytoma with Germline MAX Variant without Family History.
Hata S et al.
Clinics and Practice, 2022
35645312 (PubMed )
Supplement: clinpract-12-00035-s001.zip › clinpract-1702561-supplementary.pdf
Functional and in silico assessment of MAX variants of unknown significance.
Comino-Méndez I et al.
Journal of Molecular Medicine (berlin, Germany), 2015
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
Burnichon N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Select a paper to view details